Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
暂无分享,去创建一个
Sandra A Mitchell | E. Basch | S. Mitchell | P. Kluetz | Ethan M Basch | Paul G Kluetz | Diana T Chingos | Diana T. Chingos
[1] L. Burke,et al. Patient-reported outcomes supporting anticancer product approvals. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Basch. Toward patient-centered drug development in oncology. , 2013, New England Journal of Medicine.
[3] M. Kris,et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. , 2006, The Lancet. Oncology.
[4] D. Cella,et al. Re-personalizing precision medicine: is there a role for patient-reported outcomes? , 2015 .
[5] Steven Piantadosi,et al. Patient-centric trials for therapeutic development in precision oncology , 2015, Nature.
[6] Jay K. Harness,et al. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) , 2016, Health and Quality of Life Outcomes.
[7] Amy P Abernethy,et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.
[8] Martha Donoghue,et al. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms , 2016, Clinical Cancer Research.